<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05613777</url>
  </required_header>
  <id_info>
    <org_study_id>1346-0036</org_study_id>
    <secondary_id>2022-500050-42-00</secondary_id>
    <nct_id>NCT05613777</nct_id>
  </id_info>
  <brief_title>A Study in Healthy Women to Test Whether BI 425809 Influences the Amount of a Contraceptive in the Blood</brief_title>
  <official_title>The Effect of Multiple Doses of BI 425809 on the Pharmacokinetics of Multiple Doses of a Combination of Ethinylestradiol and Levonorgestrel Following Oral Administration in Healthy Premenopausal Female Subjects (an Open-label, Two-period, Fixed Sequence Design Trial With run-in Period)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this trial is to investigate the possible effect of multiple oral doses&#xD;
      of BI 425809 on the steady state pharmacokinetics of ethinylestradiol (EE) and levonogestrel&#xD;
      (LNG) (administered as the combined oral contraceptive Microgynon®).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 24, 2022</start_date>
  <completion_date type="Anticipated">July 24, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 24, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Fixed sequence: Run in period-Reference-Treatment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ (AUCτ,ss )</measure>
    <time_frame>Up to 22 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum measured concentration of the analyte in plasma at steady state over (Cmax,ss)</measure>
    <time_frame>Up to 22 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ(Cmin,ss)</measure>
    <time_frame>Up to 22 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Microgynon®(Run-in)/Microgynon® (treatment reference, R)/ Microgynon®+BI 425809 (treatment test, T)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Microgynon®</intervention_name>
    <description>ethinylestradiol (EE) and levonorgestrel (LNG)</description>
    <arm_group_label>Microgynon®(Run-in)/Microgynon® (treatment reference, R)/ Microgynon®+BI 425809 (treatment test, T)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 425809</intervention_name>
    <description>BI 425809</description>
    <arm_group_label>Microgynon®(Run-in)/Microgynon® (treatment reference, R)/ Microgynon®+BI 425809 (treatment test, T)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy premenopausal female subjects according to the assessment of the investigator,&#xD;
             as based on a complete medical history including a physical examination, vital signs&#xD;
             (Blood pressure(BP), Pulse rate (PR)), 12-lead Electrocardiogram (12-lead ECG), and&#xD;
             clinical laboratory tests without any clinically significant abnormalities.&#xD;
&#xD;
          -  Age of 18 to 35 years (inclusive).&#xD;
&#xD;
          -  Body mass index (BMI) of 18.5 to 29.9 kg/m2 (inclusive).&#xD;
&#xD;
          -  Signed and dated written informed consent in accordance with International Conference&#xD;
             on Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to&#xD;
             admission to the trial.&#xD;
&#xD;
          -  Female subjects who meet any of the following criteria starting from at least 30 days&#xD;
             before the first administration of BI 425809 and until 30 days after trial completion:&#xD;
&#xD;
               -  Use of adequate contraception, e.g. non-hormonal intrauterine device plus condom.&#xD;
&#xD;
               -  Sexually abstinent.&#xD;
&#xD;
               -  A vasectomised sexual partner (vasectomy at least 1 year prior to enrolment).&#xD;
&#xD;
               -  Surgically sterilised (including hysterectomy).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects will not be allowed to participate, if any of the following general criteria&#xD;
        apply:&#xD;
&#xD;
          -  Any finding in the medical examination (including BP, PR or ECG) deviating from normal&#xD;
             and assessed as clinically relevant by the investigator.&#xD;
&#xD;
          -  Repeated measurement of systolic blood pressure outside the range of 90 to 140&#xD;
             millimetre(s) of mercury (mmHg), diastolic blood pressure outside the range of 50 to&#xD;
             90 mmHg, or pulse rate outside the range of 45 to 90 beats per minute (bpm).&#xD;
&#xD;
          -  Any laboratory value outside the reference range that the investigator considers to be&#xD;
             of clinical relevance.&#xD;
&#xD;
          -  Any evidence of a concomitant disease assessed as clinically relevant by the&#xD;
             investigator.&#xD;
&#xD;
          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,&#xD;
             immunological or hormonal disorders.&#xD;
&#xD;
          -  Cholecystectomy or other surgery of the gastrointestinal tract that could interfere&#xD;
             with the pharmacokinetics of the trial medication (except appendectomy or simple&#xD;
             hernia repair).&#xD;
&#xD;
          -  Diseases of the central nervous system (including but not limited to any kind of&#xD;
             seizures or stroke), and other relevant neurological or psychiatric disorders.&#xD;
&#xD;
          -  History of relevant orthostatic hypotension, fainting spells, or blackouts. Further&#xD;
             exclusion criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CRS Clinical Research Services Mannheim GmbH</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>November 7, 2022</study_first_submitted>
  <study_first_submitted_qc>November 7, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>April 3, 2023</last_update_submitted>
  <last_update_submitted_qc>April 3, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BI 425809</mesh_term>
    <mesh_term>Ethinyl estradiol, levonorgestrel drug combination</mesh_term>
    <mesh_term>Ethinyl Estradiol-Norgestrel Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization).&#xD;
For more details refer to:&#xD;
https://www.mystudywindow.com/msw/datatransparency</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

